Sakurada, Takumi Tokushima University
Nokihara, Hiroshi Tokushima University
Koga, Tadashi Clinical Study Support
Zamami, Yoshito Okayama University KAKEN Search Researchers
Goda, Mitsuhiro Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Yagi, Kenta Tokushima University Tokushima University Educator and Researcher Directory
Hamano, Hirofumi Tokushima University KAKEN Search Researchers
Aizawa, Fuka Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Ogino, Hirokazu Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Sato, Seidai Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Kirino, Yasushi Tokushima University
Goto, Hisatsugu Tokushima University KAKEN Search Researchers
Nishioka, Yasuhiko Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
non-squamous non–small cell lung cancer
malignant pleural mesothelioma
Background: Rash eruptions are a common side-effect of pemetrexed, for which the administration of 8 mg/day of dexamethasone for 3 days from the day preceding pemetrexed administration is recommended. This study aimed to prospectively assess the effectiveness of prophylactic administration of low-dose dexamethasone for pemetrexed-induced rashes.
Methods: This single-arm, phase II study recruited patients with non-squamous non–small cell lung cancer and malignant pleural mesothelioma scheduled to receive chemotherapy including pemetrexed. Patients received 2 mg of dexamethasone daily from days 2 to 6 after chemotherapy with pemetrexed. The primary endpoint was the 3-week incidence of rash eruptions.
Results: Twenty-five patients were enrolled between September 2017 and May 2019. The incidence of rash after 3 weeks was 16.7%. Rashes erupted mainly on the upper half of the body, such as the chest and neck, and were of grades 1 and 2 in 2 patients each. No rashes of grade 3 or higher were observed, and there were no adverse events associated with additional corticosteroids.
Conclusion: Prophylactic administration of low-dose dexamethasone for 5 days from the day after pemetrexed administration resulted in a milder incidence and severity of rash. These findings may provide a standard preventative strategy for pemetrexed-induced rashes. (Trial identifier: UMIN000025666).
Oxford University Press
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
|DOI (Published Version)|
|URL ( Publisher's Version )|
oncolo_27_7_e554.pdf 220 KB